Nine of 12 Veterans Reached PTSD Remission After Psilocybin Therapy in Small Study
A small clinical trial found striking improvements among veterans with severe post traumatic stress disorder that had resisted standard care. Nine of 12 participants no longer met PTSD criteria one month after psilocybin assisted therapy. The result offers an important signal, but the study cannot prove that the treatment caused the improvement.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Takeaway | What the Study Found |
|---|---|
| Participants | Twelve United States military veterans completed the trial. |
| Treatment history | All had severe PTSD that continued despite medication and at least six months of therapy. |
| Treatment model | Participants received preparation therapy, two psilocybin sessions, and integration therapy. |
| Main result | Nine veterans showed a clinical response and reached remission after one month. |
| Safety | No serious adverse events or increases in suicidal thoughts or behavior occurred. |
| Main limitation | The study had no placebo group and reported one month outcomes. |
Do you work in the ketamine industry? Save thousands on overhead and other fees by joining the first GPO for ketamine clinics and practitioners. There’s no cost to join and zero obligations. Sign up here!
The Trial Used an Intensive Treatment Model
The Ohio State University study enrolled veterans ages 21 to 64 with severe, treatment resistant PTSD. Twelve completed the full protocol.
Treatment lasted 11 weeks. Participants first received about eight hours of preparation therapy. They then received 15 milligrams of synthetic psilocybin during a supervised session.
A second session followed two to three weeks later and used 25 milligrams. Participants also completed about eight hours of therapy after dosing.
This was not a trial of psilocybin taken alone. Therapy, clinical monitoring, preparation, and integration formed central parts of the protocol.
Symptoms Fell, With No Serious Safety Events
Clinician rated PTSD scores fell by an average of 27.5 points from baseline to the final assessment. Nine participants met the study’s definitions for both response and remission.
The three remaining veterans did not reach remission. Two showed smaller symptom reductions, while one experienced little change.
No serious adverse events occurred. The most common side effect was a mild headache. Some participants also reported brief anxiety or dizziness.
Researchers found no increase in suicidal thoughts or behavior. Heart rate and blood pressure remained within the study’s safety limits during dosing.
Could therapy explain part of the improvement? Symptoms began falling during preparation, before participants received psilocybin. The larger reduction followed the dosing sessions.
Why the Results Require Restraint
The study was designed mainly to examine safety and feasibility. It was open label, so every participant knew they would receive psilocybin.
There was no placebo group or comparison treatment. Researchers cannot separate the drug’s effects from therapy, expectations, clinical attention, or natural symptom changes.
The sample was also extremely small and highly selected. Only 12 people completed the trial from hundreds who underwent initial screening.
Researchers plan to examine outcomes through six months. They also hope to conduct a larger randomized controlled trial.
For now, the findings support continued research rather than routine clinical use. Psilocybin assisted therapy may eventually help veterans who have exhausted standard options. Larger studies must first show whether the benefits last and can be reproduced safely.
